Patents Assigned to Genentech, Inc.
  • Publication number: 20200197396
    Abstract: Provided herein are combination therapies comprising an AKT inhibitor, a PD-L1 antibody, and taxane for use in treating MTNBC and locally advanced TNBC.
    Type: Application
    Filed: December 17, 2019
    Publication date: June 25, 2020
    Applicant: Genentech, Inc.
    Inventors: NIMALI PIYUSHIKA WITHANA, ARUNA MANI, STINA MUI SINGEL
  • Publication number: 20200199639
    Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 25, 2020
    Applicant: Genentech, Inc.
    Inventors: Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
  • Publication number: 20200200752
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicants: Genentech, Inc., EPIC SCIENCES INC.
    Inventors: Omar Kabbarah, Iliana Szafer-Glusman, Dena Marrinucci, Florence Lee, Shannon Werner
  • Patent number: 10690671
    Abstract: The present invention provides methods for producing disulfide oxidoreductase A (DsbA) and disulfide oxidoreductase C (DsbC) polypeptides at very high levels of purity. Also provided are ultrapure DsbA and DsbC and methods of using same, e.g., for use in immunoassays to show removal of DsbA and DsbC from biologics produced in bacteria.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: Marc Wong, Liliana T. Yee, Amy Lim, Chris B. Fong
  • Patent number: 10689455
    Abstract: The invention provides anti-Jagged antibodies and methods of using the same.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • Patent number: 10689325
    Abstract: Processes are described for the preparation of F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Michael Jansen, Stefan Koenig, Xin Linghu, Sebastian Rieth, Nathaniel L. Segraves, Andreas Zogg
  • Patent number: 10689447
    Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: J. Michael Elliott, Justin Scheer
  • Patent number: 10690678
    Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventor: Kendall Carey
  • Patent number: 10689457
    Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: June 23, 2020
    Assignee: GENENTECH, INC.
    Inventors: Virginia Paton, Anne Blackwood Chirchir, Pam Klein
  • Publication number: 20200190030
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Publication number: 20200190061
    Abstract: The present invention provides a process for the manufacture of a compound of formula VIIIa and salts forms of VIIIa where Rc is an aryl sulfonic acid
    Type: Application
    Filed: December 18, 2019
    Publication date: June 18, 2020
    Applicant: Genentech, Inc.
    Inventors: JINGUANG LIN, ALEXANDRA CHESTAKOVA, WEI GU, HANS IDING, JING LI, XIN LINGHU, PATRIK MEIER, CHUNBO SHA, JEFFREY STULTS, YOUCHU WANG, HAIMING ZHANG, JIANQIAN ZHANG, TAO ZHANG
  • Publication number: 20200188397
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 28, 2019
    Publication date: June 18, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Patent number: 10683348
    Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee, Patrick Koenig
  • Publication number: 20200181625
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria.
    Type: Application
    Filed: August 22, 2019
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: Dorothea REILLY, Yizhou ZHOU
  • Publication number: 20200179515
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • Publication number: 20200181154
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: Roland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • Patent number: 10675367
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 9, 2020
    Assignee: Genentech Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • Patent number: 10676710
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 9, 2020
    Assignee: Genentech, Inc.
    Inventors: Natarajan Vijayasankaran, Steven J. Meier, Sharat Varma, Yi Yang
  • Publication number: 20200172569
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda
  • Publication number: 20200171029
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: September 11, 2019
    Publication date: June 4, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony ESTRADA, Alan G. OLIVERO, Snahel PATEL, Michael SIU, Joseph LYSSIKATOS